uniQure NV

uniQure NV is a US‑focused gene‑therapy company developing AAV‑based therapies for rare diseases, including HEMGENIX for hemophilia B and AMT‑130 for Huntington’s disease, underpinned by strategic licensing and Phase I/II pipeline.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 209
HQ: Amsterdam

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
QURE	uniQure NV Cap: 1.6B	EQUITY	NMS	USD	NL0010696654	Active	📈